| MeSH term | MeSH ID | Detail |
|---|---|---|
| Hepatic Encephalopathy | D006501 | 9 associated lipids |
| Weight Gain | D015430 | 101 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Glioma | D005910 | 112 associated lipids |
| Obesity | D009765 | 29 associated lipids |
| Alzheimer Disease | D000544 | 76 associated lipids |
| Peripheral Nervous System Diseases | D010523 | 33 associated lipids |
| Nervous System Diseases | D009422 | 37 associated lipids |
| Brain Edema | D001929 | 20 associated lipids |
| Starvation | D013217 | 47 associated lipids |
2-arachidonoylglycerol
2-arachidonoylglycerol is a lipid of Glycerolipids (GL) class. 2-arachidonoylglycerol is associated with abnormalities such as Atherosclerosis, Heart Diseases, Inflammatory disorder, Colitis and Peripheral Neuropathy. The involved functions are known as Immunoreactivity, inhibitors, Stimulus, Esthesia and Signal Transduction. 2-arachidonoylglycerol often locates in Back, Presynaptic Terminals, Brain region, Blood and Body tissue. The associated genes with 2-arachidonoylglycerol are ADRBK1 gene, Homologous Gene, MGLL gene, PLA2G4A gene and peptide V. The related lipids are oleoylethanolamide, Lipopolysaccharides, Promega, stearic acid and 1-stearoyl-2-arachidonoylglycerol. The related experimental models are Knock-out.
Cross Reference
Introduction
To understand associated biological information of 2-arachidonoylglycerol, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with 2-arachidonoylglycerol?
2-arachidonoylglycerol is suspected in Atherosclerosis, Heart Diseases, Sweet's Syndrome, Colitis, Dehydration, Diabetes and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 2-arachidonoylglycerol
PubChem Associated disorders and diseases
What pathways are associated with 2-arachidonoylglycerol
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with 2-arachidonoylglycerol?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with 2-arachidonoylglycerol?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with 2-arachidonoylglycerol?
Knock-out
Knock-out are used in the study 'Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice.' (Walentiny DM et al., 2015), Knock-out are used in the study 'Biochemical and pharmacological characterization of human α/β-hydrolase domain containing 6 (ABHD6) and 12 (ABHD12).' (Navia-Paldanius D et al., 2012) and Knock-out are used in the study 'Metabolic Interplay between Astrocytes and Neurons Regulates Endocannabinoid Action.' (Viader A et al., 2015).
Related references are published most in these journals:
| Model | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
NCBI Entrez Crosslinks
All references with 2-arachidonoylglycerol
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Ratano P et al. | Pharmacological inhibition of 2-arachidonoilglycerol hydrolysis enhances memory consolidation in rats through CB2 receptor activation and mTOR signaling modulation. | 2018 | Neuropharmacology | pmid:29842858 |
| Shonesy BC et al. | The initiation of synaptic 2-AG mobilization requires both an increased supply of diacylglycerol precursor and increased postsynaptic calcium. | 2015 | Neuropharmacology | pmid:25484252 |
| Shimizu T et al. | Possible inhibitory role of endogenous 2-arachidonoylglycerol as an endocannabinoid in (±)-epibatidine-induced activation of central adrenomedullary outflow in the rat. | 2015 | Neuropharmacology | pmid:25882827 |
| Eroli F et al. | Differential neuromodulatory role of endocannabinoids in the rodent trigeminal sensory ganglion and cerebral cortex relevant to pain processing. | 2018 | Neuropharmacology | pmid:29225040 |
| Walentiny DM et al. | Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. | 2015 | Neuropharmacology | pmid:25698527 |
| Pasquarelli N et al. | Evaluation of monoacylglycerol lipase as a therapeutic target in a transgenic mouse model of ALS. | 2017 | Neuropharmacology | pmid:28373073 |
| Kortleven C et al. | Neurotensin inhibits glutamate-mediated synaptic inputs onto ventral tegmental area dopamine neurons through the release of the endocannabinoid 2-AG. | 2012 | Neuropharmacology | pmid:22884466 |
| Hashimotodani Y et al. | Pharmacological evidence for the involvement of diacylglycerol lipase in depolarization-induced endocanabinoid release. | 2008 | Neuropharmacology | pmid:17655882 |
| Mátyás F et al. | Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. | 2008 | Neuropharmacology | pmid:17655884 |
| Moreira FA et al. | Reduced anxiety-like behaviour induced by genetic and pharmacological inhibition of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) is mediated by CB1 receptors. | 2008 | Neuropharmacology | pmid:17709120 |
| Chiu CQ and Castillo PE | Input-specific plasticity at excitatory synapses mediated by endocannabinoids in the dentate gyrus. | 2008 | Neuropharmacology | pmid:17706254 |
| Vellani V et al. | Functional lipidomics. Calcium-independent activation of endocannabinoid/endovanilloid lipid signalling in sensory neurons by protein kinases C and A and thrombin. | 2008 | Neuropharmacology | pmid:18329052 |
| Citraro R et al. | Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy. | 2013 | Neuropharmacology | pmid:23206503 |
| Rubio M et al. | CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats. | 2008 | Neuropharmacology | pmid:18371990 |
| Al-Hayani A et al. | The endogenous cannabinoid anandamide activates vanilloid receptors in the rat hippocampal slice. | 2001 | Neuropharmacology | pmid:11747904 |
| Suplita RL et al. | Endocannabinoids at the spinal level regulate, but do not mediate, nonopioid stress-induced analgesia. | 2006 | Neuropharmacology | pmid:16316669 |
| Darmani NA et al. | Cisplatin increases brain 2-arachidonoylglycerol (2-AG) and concomitantly reduces intestinal 2-AG and anandamide levels in the least shrew. | 2005 | Neuropharmacology | pmid:15921709 |
| Wilkerson JL et al. | The endocannabinoid hydrolysis inhibitor SA-57: Intrinsic antinociceptive effects, augmented morphine-induced antinociception, and attenuated heroin seeking behavior in mice. | 2017 | Neuropharmacology | pmid:27890602 |
| Piomelli D | The endogenous cannabinoid system and the treatment of marijuana dependence. | 2004 | Neuropharmacology | pmid:15464150 |
| Sticht MA et al. | Endocannabinoid regulation of nausea is mediated by 2-arachidonoylglycerol (2-AG) in the rat visceral insular cortex. | 2016 | Neuropharmacology | pmid:26541329 |
| Placzek EA et al. | Membrane microdomains and metabolic pathways that define anandamide and 2-arachidonyl glycerol biosynthesis and breakdown. | 2008 | Neuropharmacology | pmid:18760289 |
| Best AR and Regehr WG | Identification of the synthetic pathway producing the endocannabinoid that mediates the bulk of retrograde signaling in the brain. | 2010 | Neuron | pmid:20159441 |
| Oleson EB et al. | Endocannabinoids shape accumbal encoding of cue-motivated behavior via CB1 receptor activation in the ventral tegmentum. | 2012 | Neuron | pmid:22284189 |
| Safo PK and Regehr WG | Endocannabinoids control the induction of cerebellar LTD. | 2005 | Neuron | pmid:16301180 |
| Gantz SC and Bean BP | Cell-Autonomous Excitation of Midbrain Dopamine Neurons by Endocannabinoid-Dependent Lipid Signaling. | 2017 | Neuron | pmid:28262417 |
| Duan Y et al. | Inhibition of [3H]batrachotoxinin A-20alpha-benzoate binding to sodium channels and sodium channel function by endocannabinoids. | 2008 | Neurochem. Int. | pmid:17888543 |
| Bardell TK and Barker EL | Activation of TRPC6 channels promotes endocannabinoid biosynthesis in neuronal CAD cells. | 2010 | Neurochem. Int. | pmid:20466028 |
| Sang N et al. | Anandamide potentiation of miniature spontaneous excitatory synaptic transmission is mediated via IP3 pathway. | 2010 | Neurochem. Int. | pmid:20064571 |
| Arevalo-Martin A et al. | The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. | 2010 | Neurobiol. Dis. | pmid:20156559 |
| Piomelli D et al. | Endogenous cannabinoid signaling. | 1998 | Neurobiol. Dis. | pmid:9974178 |
| Panikashvili D et al. | The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. | 2006 | Neurobiol. Dis. | pmid:16364651 |
| Vázquez C et al. | Endocannabinoids regulate the activity of astrocytic hemichannels and the microglial response against an injury: In vivo studies. | 2015 | Neurobiol. Dis. | pmid:25917763 |
| Avraham Y et al. | Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. | 2006 | Neurobiol. Dis. | pmid:16102970 |
| Garcia-Ovejero D et al. | The endocannabinoid system is modulated in response to spinal cord injury in rats. | 2009 | Neurobiol. Dis. | pmid:18930143 |
| Melis M et al. | Protective activation of the endocannabinoid system during ischemia in dopamine neurons. | 2006 | Neurobiol. Dis. | pmid:16762556 |
| Cabranes A et al. | Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. | 2005 | Neurobiol. Dis. | pmid:16242629 |
| Fernández-Suárez D et al. | Monoacylglycerol lipase inhibitor JZL184 is neuroprotective and alters glial cell phenotype in the chronic MPTP mouse model. | 2014 | Neurobiol. Aging | pmid:24973119 |
| Feliszek M et al. | Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184. | 2016 | Naunyn Schmiedebergs Arch. Pharmacol. | pmid:26984820 |
| Schulte K et al. | Cannabinoid CB1 receptor activation, pharmacological blockade, or genetic ablation affects the function of the muscarinic auto- and heteroreceptor. | 2012 | Naunyn Schmiedebergs Arch. Pharmacol. | pmid:22215206 |
| Ameri A and Simmet T | Effects of 2-arachidonylglycerol, an endogenous cannabinoid, on neuronal activity in rat hippocampal slices. | 2000 | Naunyn Schmiedebergs Arch. Pharmacol. | pmid:10731038 |
| Ilayan E et al. | Do cannabinoids exhibit a tyramine-like effect? | 2013 | Naunyn Schmiedebergs Arch. Pharmacol. | pmid:23900610 |
| Jergas B et al. | O-2050 facilitates noradrenaline release and increases the CB1 receptor inverse agonistic effect of rimonabant in the guinea pig hippocampus. | 2014 | Naunyn Schmiedebergs Arch. Pharmacol. | pmid:24853577 |
| Hohmann AG et al. | An endocannabinoid mechanism for stress-induced analgesia. | 2005 | Nature | pmid:15973410 |
| Di Marzo V et al. | Trick or treat from food endocannabinoids? | 1998 | Nature | pmid:9872309 |
| Panikashvili D et al. | An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. | 2001 | Nature | pmid:11586361 |
| Di Marzo V et al. | Leptin-regulated endocannabinoids are involved in maintaining food intake. | 2001 | Nature | pmid:11298451 |
| Wilson RI and Nicoll RA | Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. | 2001 | Nature | pmid:11279497 |
| Stella N et al. | A second endogenous cannabinoid that modulates long-term potentiation. | 1997 | Nature | pmid:9285589 |
| Lourenço J et al. | Synaptic activation of kainate receptors gates presynaptic CB(1) signaling at GABAergic synapses. | 2010 | Nat. Neurosci. | pmid:20081851 |
| Shonesy BC et al. | CaMKII regulates diacylglycerol lipase-α and striatal endocannabinoid signaling. | 2013 | Nat. Neurosci. | pmid:23502535 |